Alere 8-K Results of Operations and Financial Condition

Exhibit 99.1

Contact:	Doug Guarino	Director of Corporate Relations	781-647-3900
	Jon Russell	Vice President of Finance

ALERE INC. ANNOUNCES

THIRD QUARTER 2012 RESULTS

WALTHAM, MA…November 8, 2012…Alere Inc.(NYSE:ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended September 30, 2012.

Financial results for the third quarter of 2012:

• Net revenue of $691.4 million for the third quarter of 2012, compared to $585.8 million for the third quarter of 2011. Non-GAAP adjusted net revenue, which includes $0.9 million in estimated revenue related to acquired software license contracts not recognized for GAAP purposes for the third quarter of 2012 due to business combination accounting rules, was $692.3 million for the third quarter of 2012, compared to $585.8 million for the third quarter of 2011.

• Net loss of $9.2 million attributable to common stockholders of Alere Inc., and respective net loss per diluted common share of $0.11, for the third quarter of 2012, compared to net income of $234.2 million attributable to common stockholders of Alere Inc., and respective net income per diluted common share of $2.48, for the third quarter of 2011. Net income for the third quarter of 2011 included a gain of $288.9 million in connection with the formation of our joint venture with the Procter & Gamble Company.

• Non-GAAP adjusted net income per diluted common share of $0.43 for the third quarter of 2012, compared to non-GAAP adjusted net income per diluted common share of $0.67 for the third quarter of 2011.

• Net product and services revenue from our Professional Diagnostics segment was $528.8 million in the third quarter of 2012, compared to net product and services revenue of $426.3 million in the third quarter of 2011. Non-GAAP adjusted net product and services revenue from our Professional Diagnostics segment, which includes $0.9 million in estimated revenue related to acquired software license contracts not recognized for GAAP purposes for the third quarter of 2012 due to business combination accounting rules, was $529.7 million in the third quarter of 2012, compared to non-GAAP adjusted net product and services revenue of $426.3 million in the third quarter of 2011. Recent professional diagnostics acquisitions contributed $134.6 million of incremental net revenue compared to the third quarter of 2011.

• North American influenza sales decreased to $9.9 million for the third quarter of 2012, from

$16.0 million for the third quarter of 2011.

• Excluding the impact of the change in North American influenza revenues and the impact on revenues of the FDA matters associated with our U.S. Alere Triage products, currency adjusted organic growth in our Professional Diagnostics segment was 1%.

• Net product and services revenue from our Health Management segment was $135.1 million in the third quarter of 2012, compared to $129.9 million in the third quarter of 2011 and $138.6 million in the second quarter of 2012. The increase in revenue from the third quarter of 2011 was related primarily to increased revenues from our home coagulation monitoring programs.

The Company’s GAAP results for the third quarter of 2012 exclude $0.9 million of revenue associated with acquired software license contracts that are not recognized due to business combination accounting rules and include amortization of $83.1 million, $3.3 million of restructuring charges, $3.6 million of stock-based compensation expense, $0.8 million of acquisition-related costs recorded in accordance with ASC 805,Business Combinations,and $1.3 million of amortization associated with fees paid for certain debt modifications and terminations, offset by $15.1 million of income recorded for fair value adjustments to acquisition-related contingent consideration. The Company’s GAAP results for the third quarter of 2011 include amortization of $70.3 million, $3.4 million of restructuring charges, $4.3 million of stock-based compensation expense, $2.9 million of acquisition-related costs recorded in accordance with ASC 805,Business Combinations, $1.3 million of amortization associated with fees paid for certain debt modifications and terminations, a $0.6 million fair value write-down in connection with an idle facility and a net unrealized foreign currency loss of $18.1 million associated with a bank account funded for the acquisition of Axis-Shield plc, offset by $3.8 million of income recorded for fair value adjustments to acquisition-related contingent consideration and a $288.9 million gain in connection with the formation of our joint venture with Procter & Gamble in May 2007. These amounts, net of tax, have been excluded from the non-GAAP adjusted net income per diluted common share attributable to Alere Inc. for the respective quarters.

Detailed reconciliations of the Company’s non-GAAP adjusted operating income and non-GAAP adjusted net income available to common shareholders to operating income and net loss available to common shareholders under GAAP, as well as a discussion regarding these non-GAAP financial measures, is included in the schedules to this press release.

The Company will host a conference call beginning at 8:30 a.m. (Eastern Time) today, November 8, 2012, to discuss these results, as well as other corporate matters. During the conference call, the Company may answer questions concerning business and financial developments and trends and other

business and financial matters. The Company's responses to these questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been previously disclosed.

The conference call may be accessed by dialing (877) 270-2148 (domestic) or (412) 902-6510 (international) and asking for Alere Inc. A webcast of the call can also be accessed via the Alere web site atwww.alere.com/investors, or directly through the following link:http://www.videonewswire.com/event.

A replay of the call will be available approximately one hour after the conclusion of the call and will remain available for a period of seven days following the call. The replay may be accessed by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and entering replay code 10020552. The replay will also be available via online webcast athttp://www.videonewswire.com/event or via the Alere web site atwww.alere.com/investors for a period of 60 days following the call.

Additionally, reconciliations to non-GAAP financial measures not included in this press release that may be discussed during the call will also be available at the Alere web site (http://www.alere.com/investors) under the Earnings Calls and Releases section shortly before the conference call begins and will continue to be available on this web site.

For more information about Alere, please visit our web site athttp://www.alere.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere enables individuals to take charge of improving their health and quality of life at home. Alere’s global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology, diabetes, oncology and women’s health. Alere is headquartered in Waltham, Massachusetts.

Source: Alere Inc.

Alere Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

	Three Months Ended September 30,
	2012			2011
Net product sales and services revenue	$	686,228		$	580,520
License and royalty revenue		5,188			5,249
Net revenue		691,416			585,769
Cost of net revenue		345,641			279,807
Gross profit		345,775			305,962
Gross margin		50	%		52	%
Operating expenses:
Research and development		40,562			34,772
Selling, general and administrative		266,481			226,271
Total operating expenses		307,043			261,043
Operating income		38,732			44,919
Interest and other income (expense), net		(55,933	)		233,319
Income (loss) before provision (benefit) for income taxes		(17,201	)		278,238
Provision (benefit) for income taxes		(10,677	)		42,652
Income (loss) before equity earnings of unconsolidated entities, net of tax		(6,524	)		235,586
Equity earnings of unconsolidated entities, net of tax		3,007			4,118
Net income (loss)		(3,517	)		239,704
Less: Net income attributable to non-controlling interests		286			138
Net income (loss) attributable to Alere Inc. and Subsidiaries		(3,803	)		239,566
Preferred stock dividends		(5,352	)		(5,358	)
Net income (loss) available to common stockholders	$	(9,155	)	$	234,208
Basic net income (loss) per common share	$	(0.11	)	$	2.84
Diluted net income (loss) per common share	$	(0.11	)	$	2.48
Weighted average shares - basic		80,792			82,486
Weighted average shares - diluted		80,792			97,090

Alere Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

	Nine Months Ended September 30,
	2012			2011
Net product sales and services revenue	$	2,051,729		$	1,717,695
License and royalty revenue		11,333			17,723
Net revenue		2,063,062			1,735,418
Cost of net revenue		1,008,608			830,521
Gross profit		1,054,454			904,897
Gross margin		51	%		52	%
Operating expenses:
Research and development		120,009			112,662
Selling, general and administrative		826,301			700,257
Total operating expenses		946,310			812,919
Operating income		108,144			91,978
Interest and other income (expense), net		(146,549	)		129,225
Income (loss) before benefit for income taxes		(38,405	)		221,203
Benefit for income taxes		(12,621	)		(4,414	)
Income (loss) before equity earnings of unconsolidated entities, net of tax		(25,784	)		225,617
Equity earnings of unconsolidated entities, net of tax		10,417			4,922
Net income (loss)		(15,367	)		230,539
Less: Net income attributable to non-controlling interests		137			160
Net income (loss) attributable to Alere Inc. and Subsidiaries		(15,504	)		230,379
Preferred stock dividends		(15,940	)		(16,682	)
Preferred stock repurchase		—			23,936
Net income (loss) available to common stockholders	$	(31,444	)	$	237,633
Basic net income (loss) per common share	$	(0.39	)	$	2.81
Diluted net income (loss) per common share	$	(0.39	)	$	2.56
Weighted average shares - basic		80,492			84,508
Weighted average shares - diluted		80,492			100,058

Alere Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands)

	September 30,		December 31,
	2012		2011
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	302,254	$	299,173
Restricted cash		3,216		8,987
Marketable securities		897		1,086
Accounts receivable, net		508,591		475,824
Inventories, net		332,512		320,269
Prepaid expenses and other current assets		153,249		188,388
Total current assets		1,300,719		1,293,727
PROPERTY, PLANT AND EQUIPMENT, NET		516,814		491,205
GOODWILL AND OTHER INTANGIBLE ASSETS, NET		4,974,806		4,676,742
DEFERRED FINANCING COSTS AND OTHER ASSETS, NET		220,342		211,027
Total assets	$	7,012,681	$	6,672,701
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Short-term debt and current portion of long-term debt	$	58,860	$	73,415
Other current liabilities		588,722		551,037
Total current liabilities		647,582		624,452
LONG-TERM LIABILITIES:
Long-term debt, net of current portion		3,541,290		3,280,080
Deferred tax liability		413,808		380,700
Other long-term liabilities		178,406		153,398
Total long-term liabilities		4,133,504		3,814,178
Redeemable non-controlling interest		—		2,497
TOTAL EQUITY		2,231,595		2,231,574
Total liabilities and equity	$	7,012,681	$	6,672,701

Alere Inc. and Subsidiaries

Reconciliation to Non-GAAP Adjusted Operating Results

(in thousands, except per share amounts)

	Three Months Ended September 30,
	2012			2011
Reconciliation to Non-GAAP Adjusted Operating Income(1)
Operating income	$	38,732		$	44,919
Revenue related to acquired software license contracts		905			—
Amortization of acquisition-related intangible assets		82,867			70,121
Restructuring charges		3,239			3,129
Stock-based compensation expense		3,626			4,286
Acquisition-related costs		833			2,912
Fair value adjustments to acquisition-related contingent consideration		(15,145	)		(3,845	)
Fair value write-down in connection with an idle facility		—			596
Non-GAAP adjusted operating income	$	115,057		$	122,118
	Three Months Ended September 30,
	2012			2011
Reconciliation to Non-GAAP Adjusted Net Income(1)
Net income (loss) available to common shareholders	$	(9,155	)	$	234,208
Revenue related to acquired software license contracts		905			—
Amortization of acquisition-related intangible assets		83,083			70,314
Restructuring charges		3,287			3,412
Stock-based compensation expense		3,626			4,286
Acquisition-related costs		833			2,912
Fair value adjustments to acquisition-related contingent consideration		(15,145	)		(3,845	)
Gain in connection with the formation of a joint venture		—			(288,896	)
Unrealized foreign currency loss associated with a bank account funded for the acquisition of Axis-Shield plc		—			18,050
Fair value write-down in connection with an idle facility		—			596
Amortization of fees paid for certain debt modifications and terminations		1,320			1,320
Income tax effects on items above		(32,931	)		16,254
Non-GAAP adjusted net income available to common shareholders	$	35,823		$	58,611
Net income (loss) per diluted common share	$	(0.11	)	$	2.48
Non-GAAP adjusted net income per diluted common share	$	0.43		$	0.67
Weighted average shares - diluted		80,792			97,090
Non-GAAP adjusted weighted average shares - diluted		84,299			97,090

⁽¹⁾  In calculating “non-GAAP adjusted operating income” and “non-GAAP adjusted net income”, the Company excludes (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from operating income and net income or loss allows investors and management to evaluate and compare the Company's operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust operating income or net income or loss for the costs associated with litigation, including payments made or received through settlements. It should be noted that “non-GAAP adjusted operating income” and “non-GAAP adjusted net income” are not standard financial measurements under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to operating income and net income or loss or cash flow from operating activities, as a measure of liquidity or as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “non-GAAP adjusted operating income” and “non-GAAP adjusted net income” presented in this press release may not be comparable to similar measures used by other companies.

Alere Inc. and Subsidiaries

Reconciliation to Non-GAAP Adjusted Operating Results

(in thousands, except per share amounts)

	Nine Months Ended September 30,
	2012			2011
Reconciliation to Non-GAAP Adjusted Operating Income(1)
Operating income	$	108,144		$	91,978
Revenue related to acquired software license contracts		3,317			—
Amortization of acquisition-related intangible assets		242,167			227,207
Restructuring charges		10,132			19,625
Stock-based compensation expense		11,868			16,275
Acquisition-related costs		6,094			6,191
Fair value adjustments to acquisition-related contingent consideration		(16,782	)		(9,684	)
Non-cash charge associated with acquired inventory		4,681			—
Fair value write-down in connection with an idle facility		—			596
Expenses incurred in connection with the sale of our vitamin and nutritional supplements business		—			23
Non-GAAP adjusted operating income	$	369,621		$	352,211
	Nine Months Ended September 30,
	2012			2011
Reconciliation to Non-GAAP Adjusted Net Income(1)
Net income (loss) available to common shareholders	$	(31,444	)	$	237,633
Revenue related to acquired software license contracts		3,317			—
Amortization of acquisition-related intangible assets		242,849			227,798
Restructuring charges		10,290			20,365
Stock-based compensation expense		11,868			16,275
Acquisition-related costs		6,094			6,191
Fair value adjustments to acquisition-related contingent consideration		(16,782	)		(9,684	)
Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility and related interest rate swap agreement		3,960			31,213
Non-cash charge associated with acquired inventory		4,681			—
Gain in connection with the formation of a joint venture		—			(288,896	)
Unrealized foreign currency loss associated with a bank account funded for the acquisition of Axis-Shield plc		—			18,050
Realized foreign currency loss associated with the settlement of an acquisition-related contingent consideration obligation		—			1,920
Fair value write-down in connection with an idle facility		—			596
Expenses incurred in connection with the sale of our vitamin and nutritional supplements business		—			23
Non-cash income allocated to net income available to common stockholders as a result of repurchases of preferred shares		—			(23,936	)
Income tax effects on items above		(93,028	)		(82,183	)
Non-GAAP adjusted net income available to common shareholders	$	141,805		$	155,365
Net income (loss) per diluted common share	$	(0.39	)	$	2.56
Non-GAAP adjusted net income per diluted common share	$	1.70		$	1.74
Weighted average shares - diluted		80,492			100,058
Non-GAAP adjusted weighted average shares - diluted		94,327			100,058

⁽¹⁾  In calculating “non-GAAP adjusted operating income” and “non-GAAP adjusted net income”, the Company excludes (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from operating income and net income or loss allows investors and management to evaluate and compare the Company's operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust operating income or net income or loss for the costs associated with litigation, including payments made or received through settlements. It should be noted that “non-GAAP adjusted operating income” and “non-GAAP adjusted net income” are not standard financial measurements under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to operating income and net income or loss or cash flow from operating activities, as a measure of liquidity or as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “non-GAAP adjusted operating income” and “non-GAAP adjusted net income” presented in this press release may not be comparable to similar measures used by other companies.

Alere Inc. and Subsidiaries

Selected Consolidated Revenues by Business Area⁽¹⁾

(in thousands)

Professional Diagnostics Segment	Q3 2012		YTD 2012		Q3 2011		YTD 2011		% Change Q3 12 v. Q3 11			% Change YTD 12 v. YTD 11
Cardiology	$	122,372	$	386,795	$	127,943	$	390,652		-4	%		-1	%
Infectious disease		136,561		425,398		142,639		405,559		-4	%		5	%
Toxicology		156,074		437,736		93,497		267,834		67	%		63	%
Diabetes		35,670		100,628		—		—
Other(1)		78,077		230,519		62,172		176,206		26	%		31	%
Professional diagnostics net product sales and services revenue(1)		528,754		1,581,076		426,251		1,240,251		24	%		27	%
License and royalty revenue		2,688		8,833		3,701		14,587		-27	%		-39	%
Professional diagnostics net revenue	$	531,442	$	1,589,909	$	429,952	$	1,254,838		24	%		27	%
Health Management Segment	Q3 2012		YTD 2012		Q3 2011		YTD 2011		% Change Q3 12 v. Q3 11			% Change YTD 12 v. YTD 11
Disease and case management	$	57,383	$	165,277	$	59,441	$	182,118		-3	%		-9	%
Wellness		24,290		80,881		24,427		80,369		-1	%		1	%
Women’s & children’s health		29,136		90,220		28,509		85,550		2	%		5	%
Patient self-testing services		24,269		68,074		17,554		60,529		38	%		12	%
Health management net revenue	$	135,078	$	404,452	$	129,931	$	408,566		4	%		-1	%

⁽¹⁾  Revenues are presented in accordance with Generally Accepted Accounting Principles and exclude an adjustment of $905 and $3,317 in revenue related to acquired software license contracts which were not recognized during the three and nine months ended September 30, 2012, respectively, due to business combination accounting rules.